Human Biomarkers Core

人类生物标志物核心

• 批准号: 10687208
• 负责人: LEONARD PETRUCELLI
• 金额: $ 35.22万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-15 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10687208
• 关键词: Addendum; Age; Antibodies; Autopsy; Biological Assay; Biological Markers; Biological Models; Brain; Brain region; Cell Nucleus; Cells; Cerebrospinal Fluid; Characteristics; Clinic; Clinical; Code; Collaborations; Communities; Data; Data Set; Dedications; Detection; Diagnostic; Disease; Disease Progression; Doctor of Philosophy; Ensure; Evaluation; Event; Exons; Frontotemporal Dementia; Frontotemporal Lobar Degenerations; Functional disorder; Genetic; Genomics; Goals; Human; Human Genetics; Immunoassay; Induced pluripotent stem cell derived neurons; Light; Measures; Methods; Mining; Monitor; Nature; Nerve Degeneration; Neurology; Neurosciences; Onset of illness; Pathogenesis; Pathology; Patients; Peptides; Phosphorylation; Plasma; Process; Production; Prognostic Marker; Program Development; Protein Isoforms; Proteins; Proxy; RNA; RNA Splicing; Research; Research Project Grants; Resolution; Resources; Role; Sampling; Severity of illness; Specificity; Surrogate Markers; Testing; Time; Tissue Sample; Tissues; Transcript; Translating; Validation; Variant; Vision; Work; biomarker development; biomarker panel; brain tissue; candidate marker; cryptic protein; design; diagnostic biomarker; empowerment; genetic risk factor; high resolution imaging; human imaging; human tissue; innovation; insight; multimodality; neurofilament; novel; prognostic; prognostic value; programs; protein TDP-43; research and development; specific biomarkers; stathmin; therapeutic development; therapeutic target; tool; transcriptome sequencing; web portal

Project Summary The overall goal and singular focus of our proposed Center Without Walls is to unravel the mechanisms of FTLD-TDP. We have formed a diverse interdisciplinary team to tackle this challenge. Our team brings together experts in genetics, genomics, neuroscience, neurology, and pathology. We have FTLD experts as well as outsiders who bring new perspectives and key resources and approaches to the field. Our team has also recently made an unexpected discovery of a new splicing target of TDP-43, which provides a direct and surprising connection to FTD human genetics and will be a launching pad for defining the mechanisms of FTLD-TDP. We posit that mis-splicing events caused by TDP-43 dysfunction may well be the earliest events in the process. Our vision is to create a Center dedicated to providing unprecedented access to TDP- 43 function, even before it is depleted from the nucleus. Rather than have human genetics as an afterthought or addendum, we endeavor to have the genetics deeply integrated in our program from Day 1. Our Center will make all of the data and code we generate freely available via a web portal that contains high resolution images of human brains across different subtypes of FTLD- TDP showing, at cellular resolution, TDP-43 localization along with a panel of cryptic splicing readouts as sensitive beacons of TDP-43 activity in different brain regions. This will empower the broad FTLD research community to generate (and test) new hypotheses about disease mechanisms and to have at their disposal sensitive biomarkers. Our Center will launch multimodal efforts to 1) comprehensively discover the TDP-43 splicing targets relevant to human FTLD-TDP; 2) define the mechanisms by which TDP-43-dependent cryptic exon splicing events contribute to neurodegeneration, using model systems and human tissues; 3) harness these novel cryptic exons to generate highly sensitive and specific biomarkers for the FTD field; 4) innovate genomics analysis methods to integrate human genetics data and RNA sequencing data and make these resources available to the community to discover how genetic risk factors for FTD contribute to cryptic exon splicing and vice versa. We strongly suspect that we will discover the cryptic exon splicing code that serves as the Achilles’ heel to drive neurodegeneration in FTLD-TDP.

项目摘要 我们提出的无墙中心的总体目标和单一重点是解开 FTLD-TDP的机制。我们组建了一支多元化的跨学科团队来解决这个问题 挑战.我们的团队汇集了遗传学、基因组学、神经科学、神经病学和 病理我们有FTLD专家以及外部人士，他们带来了新的观点和关键 资源和外地办法。我们的团队最近还意外地发现 TDP-43的一个新的剪接靶点，它提供了与FTD的直接和令人惊讶的联系， 人类遗传学，并将成为定义FTLD-TDP机制的出发点。我们断定 由TDP-43功能障碍引起的错误剪接事件很可能是 过程我们的愿景是创建一个中心，致力于提供前所未有的访问TDP- 43功能，甚至在它从核中耗尽之前。而不是把人类遗传学作为 事后的想法或补充，我们奋进有遗传学深入融入我们的计划 从第一天开始。我们的中心将通过网络免费提供我们生成的所有数据和代码 包含不同FTLD亚型的人脑高分辨率图像的门户网站- TDP显示，在细胞分辨率下，TDP-43定位沿着一组隐蔽剪接 作为TDP-43在不同大脑区域活动的敏感信标。这将使 广泛的FTLD研究社区，以产生（和测试）关于疾病的新假设 机制，并拥有敏感的生物标志物。我中心将推出多式联运 1）全面发现与人FTLD-TDP相关的TDP-43剪接靶点; 2)明确TDP-43依赖性隐蔽外显子剪接事件有助于 神经变性，使用模型系统和人体组织; 3）利用这些新的隐蔽的 外显子，为FTD领域产生高度敏感和特异性的生物标志物; 4）创新基因组学 整合人类遗传学数据和RNA测序数据的分析方法， 社区现有的资源，以发现FTD的遗传风险因素如何促成 隐蔽外显子剪接，反之亦然。我们强烈怀疑我们会发现隐藏的外显子 剪接代码，其充当驱动FTLD-TDP中神经变性的阿喀琉斯之踵。